Japanese pharmaceutical company Daiichi Sankyo Co. announced Monday it had agreed to acquire US company Ambit Biosciences for $410 million.
The company said the move was a bid to establish its presence in the oncology field. Oncology is a branch in medicine that deals with tumors.
The Japanese company will need to spend $315 million to acquire all the stocks of Ambit Biosciences, a joint statement said. Sankyo President Joji Nakayama said in the statement that the move will ensure Sankyo will continue to provide innovative pharmaceuticals in areas that are unmet in terms of medical need.
GMT 22:53 2018 Thursday ,13 December
Indian Minister of Trade meets with UAE Ambassador, Chairman of Emaar PropertiesGMT 13:41 2018 Thursday ,06 December
Tyre maker Continental opens lab to extract rubber from dandelionsGMT 15:22 2018 Friday ,30 November
Paper industry around famous Chinese lake to be shut down by 2019GMT 11:13 2018 Sunday ,18 November
Electricx 2018 kicks off with participation of over 20 countriesGMT 14:17 2018 Thursday ,25 October
BP eyes entering several new Rosneft projectsGMT 12:08 2018 Saturday ,20 October
OPEC participants performed Vienna Agreement by 111%GMT 16:14 2018 Saturday ,06 October
Saudi Aramco IPO to go ahead by early 2021GMT 19:01 2018 Thursday ,04 October
LEAD S. Korean firms offer aid for quake-hit IndonesiaMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor